Next Phase Newsletter

A corporate venture capital firm that was launched within the last year was operating in stealth for the year prior. The firm prefers to invest in Series A, though can also invest in Seed and Series B if there is a great fit. The firm invest in pre-clinical stage and devices already with FDA approval. The firm is a hands-on investor, providing value and leverageable knowledge to the companies from both investor team and the corporation. The firm invests globally with a first ticket of €1-3M. 

 
The firm is largely focused on investing in diagnostics and digital solutions, as well as select life science tools. 
 
The firm prefers to syndicate with other VCs or CVCs, and typically requires a board seat as part of the  hands-on approach to the company. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

An investment firm founded in 2015 invests in technology, medical, and science-related deals. The firm typically engages in late Seed and Series A financings with typical check size being around $2M. Though the firm’s first searches are in the Midwest US, they are open to all investment opportunities across the US – generally, the firm avoids Boston and Silicon Valley. The firm will lead about half of its investments. 
 
Within life sciences, the firm invests in all sectors but is currently focusing on therapeutics and diagnostics companies. The firm is generally indication-agnostic, but in terms of diagnostics, they are focusing on cancer. For therapeutics companies, the firm prefers them to be about a year before conducting human trials. For medical devices, diagnostics, and digital health, companies should be pre-revenue and pre-FDA approval. 
 
The firm does not require to take a board observer seat but may take one depending on the case. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A Biotech & Life Science strategic partner with a venture capital fund is currently investing from their second fund, which is roughly USD $50M and targeted to reach $100M. The firm typically invests between $1-3M into startups seeking seed round funding. The fund invests solely in the form of equity and is open to global investments within North America and Europe. 

The firm also serves as a Strategic Partner for its network of investors actively looking for curated investments that fit their criteria as a result provides capital raise support for life science companies in this regard. Investors in our networks are actively seeking companies in clinical development and can fund from $5M-$100M based on stage of development. 

In addition, the firm offers its strategic hub to provide innovative solutions to address many challenges they face. 
 
The firm invests primarily in therapeutic companies. The firm is opportunistic with regards to indication and open to investment opportunities within CNS, chronic diseases, rare diseases, and oncology. The firm invests in companies using tissue engineering/ tissue remediation modalities. For investment opportunities outside of therapeutics, such as SAAS companies or digital health platforms, the firm can connect startups with their investment network. 
 
The firm does not have any strict company/ management team requirements. The firm is open to global investment opportunities and prefers these international investments to seek distribution rights within the US. The firm typically does not seek a board seat on their investments, as they largely prefer to co-invest and do not lead rounds. The firm prefers management teams with previous exits/ experience. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A $400 million strategic corporate venture capital funded by a full-fledged oncology pharmaceutical company headquartered in Japan seeks to make equity investment in startup companies that discover and develop innovative therapeutic products and/or drug-enabling platform technologies that demonstrate a clear potential to benefit cancer patients. Investment size can be flexible depending on the deal. The firm will also consider the option-type of investments and spin-outs, in addition to pure equity investments. The fund is currently seeking opportunities in the USA, Europe and Japan, the focus being mainly in the US and Europe.

The firm will consider early-stage (generally research to pre-IND) first-in-class/new biology-based approaches in drug discovery and innovative platform technologies for drug discovery, especially assets that have a strategic angle to TPC’s pipeline. The firm considers a wide variety of modalities (biologics/oncolytic viruses and small molecules) as well as cell and gene therapy on an opportunistic basis. The firm’s primary indication of interest is oncology, but the firm is also interested in immunology, allergy, musculoskeletal, and orphan indications.

While the firm is primarily focused on therapeutics, the firm may review technologies in medical device, diagnostic, or digital health sectors on a very selective basis if there is a strong strategic alignment.

The firm is looking for teams with strong sector expertise. With the support of the parent corporation’s established expertise in the field of oncology product discovery and development, the firm will provide financial resources and company outreach to build strategic alliances to help translate novel research and high potential drug candidates into cornerstone products. The firm may request regional option or rights on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A newly established venture capital firm based in the USA is investing globally in medically related early-stage companies. Initial size of investment ranges from $250 – 500K. While the firm is focused on USA-based companies, the firm is open to considering companies across the globe.

The firm invests in medtech and digital health companies. While the founder has decades of experience as an oculofacial plastic surgeon, the firm is generally opportunistic and will consider any promising technologies that address unmet medical needs. The firm has looked at AI companies, digital health/software companies implementable in medical practices, etc. In terms of stage of development, the firm is open to investing as early as pre-prototype, given that the company has properly researched the idea behind their technology.

The firm has no specific company or management team requirements, and is open to acting as either a lead or co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A venture capital firm founded in 2017 and is based in Cambridge, MA. The firm focuses on biotech investments with particular interest in the following indications: oncology, immunology, CNS/neurology, among others. The firm also invests in rare and orphan diseases. The firm is generally stage agnostic, and can invest in anywhere from pre-clinical to pre-launch, commercial stage companies. The firm is capable of investing up to $15M over the life of the company, and is open to acting as either the lead/co-lead or co-investor.

The firm focuses on investments in therapeutics companies across all stages of development, from pre-clinical, clinical, to commercial stage. The firm is most interested in indications of high unmet medical need, including oncology, immunology, neurology, and rare diseases and may seek assets in other indications on a case-by-case basis.

The firm seeks to work with companies backed by an experienced management team with strong scientific expertise. The firm invests in both public and private companies, and is open to acting as either the lead/co-lead or co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A life sciences-focused, impact venture capital firm was founded in 2018 and headquartered in New York with offices in Zurich. The firm aims to achieve meaningful social impact in both developed and emerging markets in addition to financial returns. The firm participates in Series A onward rounds, acting as a lead or co-investor, but can engage with companies earlier depending on the nature of the technology and target indications. Initial check sizes range from USD $3-12M with additional capital generally reserved for follow-ons. The firm is open to global companies.

The firm finances promising life science technologies for high-burden public health challenges and threats. This includes, but is not limited to, infectious diseases, maternal and child health, antimicrobial resistance, and malnutrition, and other related global health indications. In terms of technologies, the firm has a broad mandate and invests in vaccines, therapeutics, medical devices, diagnostics, and related enabling technologies. The firm generally likes to see opportunities that have demonstrated safety and generated efficacy signals from clinical trials or similar evaluations and compelling proof-of-concept data.

The firm generally prefers to take a board observer seat at minimum. The firm likes to be an active investor such as being involved in corporate strategy and company building.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.